
|Videos|November 7, 2022
Dr. Goldberg explains disparities in shared decision-making for prostate cancer screening
Author(s)Urology Times staff
“We do know that for these specific racial minorities, more time and more tools need to be invested in order to have both the rates of PSA discussion and PSA testing equal to those that White men have,” says Hanan Goldberg, MD, MSc.
Advertisement
Hanan Goldberg, MD, MSc, discusses the sociodemographic disparities found in his recent study on shared decision-making for prostate cancer screening, which was presented at the 74th Annual Meeting of the Northeastern Section of the American Urological Association. Goldberg is an assistant professor at SUNY Upstate Medical University in Syracuse, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
4
EV plus pembro approval reframes first conversation in MIBC diagnosis
5













